|SAMe Research||| Print ||
Numerous scientific studies suggest that SAMe may help treat depression. Controlled trials have found SAM-e to be more effective than placebo and equal in efficacy to the tricyclic antidepressants for treating major depressive disorder when given either intravenously or as an injection. Only recently have researchers studied the effects of SAMe taken by mouth. Thus less evidence supports the use of oral SAM-e, although some trials have shown its effectiveness as well.
Papakostas GI, Mischoulon D, Shyu I, et al. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry. 167(8):942-8, 2010.
Papakostas GI. Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major
depressive disorder. J Clin Psychiatry. 70 Suppl 5:18-22, 2009.
Ravindran AV, Lam RW, Filteau MJ, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. V. Complementary and alternative medicine treatments. J Affect Disord. 117 Suppl 1:S54-64, 2009.
Williams AL, Girard C, Jui D, Sabina A, Katz DL. S-adenosylmethionine (SAMe) as treatment for depression: a systematic review. Clin Invest Med. 28(3):132-9, 2005.
Alpert JE, Papakostas G, Mischoulon D, et al. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. . J Clin Psychopharmacol. 24(6):661-4, 2004.